Evidence map›Paper›PMID 37246200›Full record

ArticleSignal transduction and targeted therapy2023

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade.

Si-Chong Han, Gui-Zhen Wang, Ya-Ning Yang, Wen-Feng Fang, Bei-Bei Sun, Jian-Dong Zhang, Hua-Qiang Zhou, Li Zhang, Yan Wang, Guang-Biao Zhou

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. A Di-Rhamnolipid (RhaBioFactors (Oxford, England)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Si-Chong Han *State Key Laboratory of Molecular Oncology and Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gui-Zhen Wang *State Key Laboratory of Molecular Oncology and Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ya-Ning Yang *State Key Laboratory of Molecular Oncology and Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wen-Feng Fang *Lung Cancer Research Centre and State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Bei-Bei Sun *State Key Laboratory of Molecular Oncology and Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jian-Dong ZhangShanxi Bethune Hospital Affiliated with Shanxi Academy of Medical Sciences, Taiyuan, China.
Hua-Qiang ZhouLung Cancer Research Centre and State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Li ZhangLung Cancer Research Centre and State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China. zhangli@sysucc.org.cn.
Yan WangState Key Laboratory of Molecular Oncology and Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. wangyanyifu@163.com.
Guang-Biao ZhouState Key Laboratory of Molecular Oncology and Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. gbzhou@cicams.ac.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNSun Yat-sen University · CNNational Cancer Center · USShanxi Academy of Medical Sciences · CNSun Yat-sen University Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalB7-H1 AntigenHumansProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalB7-H1 AntigenProgrammed Cell Death 1 Receptor

Identifiers

PMID37246200
PMCPMC10225463
OpenAlexW4378628084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.